Since the beginning, The Max Foundation’s focus has been developing the systems needed to deliver life-extending drugs safely and effectively to patients in low- and-middle-income countries, demonstrating that it can indeed be done. Our mission in the next five years is to change perceptions so it will no longer be acceptable to leave these patients behind.
Our Approach
To accelerate health equity, The Max Foundation structures its programming in three categories.
Through our flagship program, Max Access Solutions, we deliver medication to support patients living in low- and middle-income countries in partnership with their specialists and treating institutions. It’s a groundbreaking model that prioritizes individual patients’ needs with the sophistication and flexibility to fit local regulations.
Beyond treatment, our programming also contributes to Health System Strengthening by increasing diagnostic capacity, bolstering patient advocacy, and providing clinical education, support care, and disease management. We also focus on the Social Determinants of Health. On any given day, our global team provides psychosocial support, transportation assistance, adherence monitoring, and more to ensure the needs of patients across the globe are handled individually and holistically.
Within each of these programmatic areas, we are constantly developing solutions to increase operational efficiency and further our impact. Our Max Innovation Lab serves as a platform for idea incubation, programmatic design, and implementation. Often, our innovation lab pilots begin in a particular country or region and once the intended effect has been demonstrated and its value proven, it’s scaled globally.
Our Future
I was, and still am, a beneficiary of The Max Foundation. I was diagnosed with chronic myeloid leukemia when I was a first-year resident. The life-saving service Max provided was the inspiration that led me to study hematology and forever strive to pay the debt forward.
Dr. Fisihatsion Tadesse and his family from Ethiopia
| Core Goals by 2027, we will… | Five-Year Metrics by 2027 we will… |
|---|---|
| Double the number of new patients we help each year | Treat an additional 25,000 newly diagnosed patients and provide an additional 50,000 molecular diagnostic tests |
| Double the number of diseases we support | Increase our portfolio to help patients afflicted with 20 diseases for which treatment is not accessible in their country |
| Double the number of donors in the Humanitarian Partnership for Access to Critical Treatment | Increase the size of our Humanitarian Partnership for Access to Critical Treatment to 10 donors |
| Expand geographically to provide targeted access where there is none today | Establish access programs in 10 new countries to increase our reach to 85 |
2022-2027 Key Priorities
Treat More Patients
+ Invest in our regional teams and strengthen our local presence
Our regional teams are our greatest asset and facilitate all our patient programming across the globe. Over the next five years we will build on these already robust regional teams and expand our local capability through recruitment, training, and support. Our expansive network of physicians and partner institutions are part of these teams, and we will increasingly supply them with enhanced information and tools.
+ Expand global programs to new countries
We plan to launch operations in 10 new countries to enable physicians to provide life-extending treatment to patients currently without access. This will require a new and expanded physician network capable of prescribing and supporting new treatments as well as relationships with new partner institutions around the world.
Amplify Our Voice
+ Amplify our patients’ voices
Access to life-extending medication and quality healthcare is a human right. The fact that some patients receive treatment for their illness while others are denied care is unjust and unacceptable. In the next five years, we will amplify patients’ voices and share their sense of urgency. Further, we plan to expand our research capacity so new knowledge can be generated for the betterment of all patients. We will speak out more forcefully, and in more high-profile settings, about the moral imperative we all share to ensure patient access to innovative, high-impact medicine worldwide.
+ Expand the impact of our programs on countries’ health systems
Our work is not simply Max Access Solutions. We witness the daily impact of our programming on the health systems of the countries in which we work. We plan to double down on this programming and scale up our work in diagnostics, physician support, patient education, data systems and sharing, global advocacy, and other vital strategies that improve the overall health systems we support. It is possible and sustainable to both address the urgent needs of patients and collaborate on health system strengthening around the world.
Sustain Our Work Through Robust Partnerships
+ Expand our Humanitarian Partnership for Access to Critical Treatment (HPACT)
Expanding our current pharmaceutical collaborations is critical. It will enable us to expand our programming to treat more illnesses and serve more patients. It will also further promote a collaboration focused on ensuring global access to all new medications.
+ Strengthen organizational and operational systems
We believe in maximizing the value we bring to patients through improved efficiency and expanded capacity. We are constantly working to ensure that our operational and programmatic costs facilitate the greatest care for patients in our programs. We will continue to pursue systematic improvements to our operational procedures, workforce development, training, and supply chain activities.